New problems in GABA-ergic pharmacology of anxiety

Eksperimental'naya i Klinicheskaya Farmakologiya

Volumn 60, Issue 5, 1997, Pages 6-7

  Kaluev, A V ^a  

^a Center of Physiobiological Problems   (Ukraine)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0346542468     PISSN: 08692092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. R. E. Adamec and T. Shallow, Physiol. Behav., 7, 101-109 (1993).
2. J. D. Brioni, Drug Dev. Res., 28(1), 3-19 (1993).
3. J. C. Cole and R. J. Rodgers, Behav. Pharmacol., 4, 573-580 (1993).
4. E. Costa, in: Anxiety and the anxiety disorders, London (1985), pp. 27-52.
5. N. J. Coupland and D. J. Nutt, in: Cholecystokinin and anxiety: from Neuron to Behavior, New York (1995), pp. 1-32.
6. J. N. Crawley, Neurosci. Biobehav. Rew., 9, 37-44 (1985).
7. M. Davis, D. Rainie, and M. Cassel, Tr. Neurosci., 17(5), 209-214 (1994).
8. A. J. Dunn and C. W. Berrige, in: Neuromethods (Vol. 3 - Peptides 3), New York (1987), pp. 3229-3473.
9. S. E. File, Behav. Brain. Res., 58, 199-202 (1993).
10. S. E. File, C. Fernandas C., Anxiety, 1, 8-12 (1994).
11. S. E. File, in: GABA-A reseptors and anxiety: From neurobiology to treatment, New York (1995), pp. 93-113.
12. S. E. File, Pharmacol. Biochem. Behav., 54(1), 3-12 (1996).
13. J. A. Gray, S. Quintero, J. Mellanby, et al., in: Actions and interactions of GABA and Benzodiazepines, New York (1984), pp. 239-262.
14. J. A. Gray, The neuropsychology of emotion and personality, Cognitive neurochemistry, Oxford (1987).
15. G. Gribel, C. Belzung, R. Misslin, and E. Vogel, Behav. Pharmacol., 6, 811 (1993).
16. G. Griebel, D. J. Sanger, G. Perrault, Psycopharmacol., 124, 245-254 (1996).
17. W. Haefely, The role of GABA in anxiolytic / antidepressant drug action. Experimental approaches to anxiety and depression, Chichester (1992).
18. G. A. Higgins, P. Nguen, J. A. Sellers, Brain Res., 572(1-2), 208-215 (1992).
19. A. J. Greenshaw, T. V. Nguyen, D. J. Sanger, in: Neuromethods (Vol. 10, Analysis of psychiatric drugs), Clifton, NJ (1988), pp. 1379-1427.
20. J. Harro, in: Methods in Neurosciences (Vol. 14, Paradigms for the study of Behavior), San Diego, New York (1993), pp. 359-377.
21. S. Hogg, Pharmacol. Biochem. Behav., 54, 21-30 (1996).
22. I. Izquierdo and J. H. Medina, Treds Pharmacol. Sci., pp. 260-265 (1991).
23. H. C. Jackson and D. J. Nutt, Europ. J. Pharmacol., 221, 199-203 (1992).
24. S. Jacobson, Amer. J. Psych., 124, 999 (1968).
25. A. V. Kalueff, Abstr. Internat. Behav. Neurosci. Soc., 5, 44 (1996).
26. A. V. Kalueff, D. J. Nutt, Anxiety (1997) (in press).
27. A. E. Kelly, M. Cador, and L. Stinus, in: Neuromethods (Vol. 13, Psychopharmacology), Clifton, New York (1989), pp. 95-144.
28. B. E. Leonard, in: Human Psychopharmacology: Measures and Methods (Vol. 2), Chichester, New York, 334-345.
29. A. S. Lippa, P. A. Nash, E. N. Greenblatt, in: Industrial pharmacology (Vol. III, Anxiolytics), New York (1979), pp. 41-66.
30. K. G. Floyd, P. L. Morselli, in: Phychopharmacology, New York (1987), pp. 183-194.
31. R. L. MacDonald and R. W. Olsen, Ann. Rev. Neurosci., 17, 569-602 (1994).
32. J. L. McGaugh, Brain. Res. Bull., 23(4-5), 339-345 (1989).
33. J. L. McGaugh, in: Psycopharmacology: A review of the Progress 1957-1967, Washington D. C. (1968), pp. 891-904.
34. N. McNaughton, in: Stress - From synapse to syndrome, London (1993), pp. 191-206.
35. D. J. Nutt, Pharm. Ther., 47, 233-266 (1990).
36. D. J. Nutt, in: Receptor data for biological experiments: a guide to drugs selectivity, London (1991), pp. 225-229.
37. R. D. Porsolt, R. A. McArthur, A. Lenegre, in: Methods in behavioral pharmacology, New York (1993), pp. 23-51.
38. E. Rodin, EEG Clin. Neurophysiol, 10, 433-446 (1958).
39. R. J. Rodgers, J. C. Cole, Physiol. Behav., 53, 383-388 (1993).
40. R. J. Rodgers and J. K. Shepherd, Psychopharmacol., 113, 237-242 (1993).
41. R. J. Rodgers, J. C. Cole, A. Davies, Pharmacol. Biochem. Behav., 48(4), 959-963 (1994).
42. R. J. Rodgers, J. C. Cole, in: Ethology and Psychopharmacology, Chichester (1994), pp. 9-44.
43. R. J. Rodgers, J. C. Cole, K. Aboulta, L. H. Stetenson, Pharmacol. Biochem. Behav., 5(3), 1-9 (1995).
44. R. J. Rodgers, J. T. Johnson, S. L. Norton, and J. C. Cole, J. Psychopharmacol. 1(1), 38-42 (1995).
45. W. Sieghart, Trends Pharmacol. Sci., 13, 446-450 (1992).
46. W. Sieghart, Pharmacol. Rev., 47(2), 181-234 (1995).
47. Sherif, Pharmacol. Behav., 45, 231-236 (1995).
48. L. S. von Meduna and E. Friedman, Psychoses, 112(6), 501-509 (1939).
49. E. R. Vonkerts, NIDDR Utrecht, pp. 1-253 (1995).
50. P. Willner, in: Methods in Neurosciences (Vol. 14, Paradigms for the study of behavior), San Diego, New York (1993), pp. 145-162.